IceCure’s ProSense Cryoablation Evaluated to Treat Breast Cancer in Single-Center Study

August 14, 2024—IceCure Medical Ltd., developer of minimally invasive cryoablation technology to destroy tumors, announced the publication of findings from an independent, single-center study on cryoablation for the treatment of early breast cancer in nonsurgical patients.

The study was led by Lucia L. Graña-López, PhD, and conducted by investigators in the radiology, oncology, and surgery departments at Hospital Lucus Augusti in Lugo, Spain. Dr. Graña-López et al published the findings online in British Journal of Radiology.

According to the company, the study aimed to evaluate the acceptance of percutaneous cryoablation treatment by patients with early stage breast cancer who choose not to have surgery. Of the 45 patients offered cryoablation with IceCure’s ProSense system, 43 patients (95.6%) accepted. Of these, 36 patients, representing 39 malignant tumors (median size, 24 mm), proceeded to undergo cryoablation.

The median age of patients treated with cryoablation was 87 years, with a range of 60 to 96 years. After a median follow-up of 16 months, the complete ablation rate in luminal breast cancer with tumors ≤ 25 mm was 100%. No major complications were seen, stated IceCure.

As summarized in the company’s press release, the study investigators concluded the following:

• Most nonsurgical patients with early stage breast cancer accepted cryoablation when the treatment was offered.
• Cryoablation is safe, effective, and well tolerated as an outpatient procedure.
• Outcomes suggest cryoablation could be an alternative to surgery for the management of breast cancer in this group of patients—noting the financial, physical, and cosmetic benefits of the treatment.

IceCure Medical’s flagship ProSense system is marketed and sold worldwide—including in the United States, Europe, and China—for the indications cleared and approved to date.